Shiseido to Acquire Dr. Dennis Gross Skincare
Shiseido Company, Limited (The Prime Market of the Tokyo Stock Exchange: 4911) (“Shiseido”, “Company”) today announced that Shiseido Americas Corporation (“Shiseido Americas”), a subsidiary of Shiseido, has signed a definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare brand which offers dermatologist-led, science-based prestige skincare that has revolutionized the beauty industry by bringing high-level products to consumers everywhere.
In support of Shiseido’s corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD”, the acquisition of Dr. Dennis Gross Skincare is a synergistic complement to the Company’s skin beauty strategic framework and global portfolio of prestige brands. With the addition of Dr. Dennis Gross Skincare, Shiseido seeks to accelerate and strengthen its core prestige skincare business which includes brands SHISEIDO and Clé de Peau Beauté.
Dr. Dennis Gross Skincare was launched in 2000 by former skin cancer researcher and practicing dermatologist, Dr. Dennis Gross, and his wife, Carrie Gross. Dr. Dennis Gross Skincare’s best-in-class products are distinctive and highly effective, leveraging active ingredients with proven skincare benefits. Dr. Dennis Gross Skincare values industry-changing innovation and has a philosophy that is rooted in research, dermatology, and technology.
As part of the Shiseido portfolio, Dr. Dennis Gross Skincare will leverage the Company’s vast global support network, commercial experience, and R&D expertise, enabling the brand to accelerate its ambitious growth plans. Shiseido’s proven expertise in skincare will facilitate Dr. Dennis Gross Skincare’s long-term growth trajectory. Additionally, this acquisition bolsters the Company’s geographic diversification and reinforces its investment in the Americas, with an aim to accelerate growth and increase profitability in the region.
Masahiko Uotani, Chairman and CEO of Shiseido, said, “This transaction is well-aligned with Shiseido’s 2030 goal of becoming a personal beauty wellness company that supports people in realizing unique beauty and wellness throughout their lives. Dr. Dennis Gross Skincare is the perfect complement to our global portfolio of prestige brands as their core values are aligned with ours in terms of their scientific and innovative approach to beauty and our people-first culture. We are thrilled to welcome the Dr. Dennis Gross Skincare team to the Shiseido family, and I am confident Dr. Dennis Gross Skincare will accelerate our growth in the Americas, a region that has experienced strong business performance, thanks to our portfolio of exceptional brands.”
Shiseido Americas President and CEO and Global M&A Leader for Shiseido, Ron Gee, added, “We have long-admired what Carrie Gross has built through innovation and disruption of the beauty industry as well as the unique way in which the brand delivers credible and effective products through research, accessibility and education. We are also excited to work with Dr. Dennis Gross, a practicing, world-renowned, board-certified dermatologist whose work has attracted a loyal and highly engaged consumer base. With our deep commitment to our teams and our consumers, I know Dr. Dennis Gross Skincare will thrive in the Shiseido portfolio.”
Dr. Gross, Co-Founder of Dr. Dennis Gross Skincare and Chief Science Officer and Carrie Gross, Co-Founder and Chief Executive Officer said, “We launched Dr. Dennis Gross Skincare in 2000 with the mission of making a difference in the lives of all people everywhere by helping them achieve healthier skin. We’ve built an incredible brand with a deep clinical foundation and loyal consumer base, and we are thrilled to have found a partner that shares our values. With its long and rich heritage blending beauty with science, Shiseido is the ideal home for Dr. Dennis Gross Skincare, and we look forward to partnering with the Shiseido team as we continue developing innovative products and skincare solutions that deliver visible results.”
The transaction was led by Shiseido Americas and the New York-based Shiseido Global M&A team, in close coordination with Shiseido Company, Limited, the Company’s headquarters. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close in the first quarter of 2024. Terms of the transaction were not disclosed.
Jones Day served as Shiseido Americas’ legal counsel. Raymond James served as Dr. Dennis Gross Skincare’s exclusive financial advisor. Cowan, DeBaets, Abrahams & Sheppard LLP served as legal counsel to Dr. Dennis Gross Skincare, and Morrison Foerster served as legal counsel to certain of the shareholders.
About Shiseido Company, Limited
Shiseido was founded in 1872 as the first private Western-style pharmacy in Japan. The business gradually evolved into a cosmetics company, offering people the most advanced technology and the finest aesthetics available across the world. Now known globally as the premier cosmetics company with roots in Japan, the name Shiseido has come to represent the world’s highest standards of quality. Fiercely contemporary and innovative after over 150 years in business, Shiseido Group brands are now sold in over 120 countries and regions. With its new Medium-to-Long-Term Strategy “SHIFT 2025 and Beyond”, Shiseido aims to become a “PERSONAL BEAUTY WELLNESS COMPANY” by 2030, realizing its corporate mission, BEAUTY INNOVATIONS FOR A BETTER WORLD. For more information, please visit https://corp.shiseido.com/en/.
About Dr. Dennis Gross Skincare
Launched in New York City in 2000, Dr. Dennis Gross Skincare is a skincare brand founded by former skin cancer researcher and practicing dermatologist Dr. Dennis Gross along with his wife Carrie Gross. Together, they disrupted the beauty industry by asking people to peel daily with their now-iconic Alpha Beta® Daily Peels. With innovative, patented formulas incorporating simple, straightforward instructions, clients became instant believers. Today the Alpha Beta Peel is the #1 at-home peel in the US and a staple in the beauty cabinets of top celebrities, aestheticians, and makeup artists. Dr. Gross continues to bring innovations and expertise from the dermatology practice to retail consumers around the globe in the form of easy-to-use at home products designed to work together in customizable regimens to treat multiple concerns. For more information, visit the brand on Instagram, Facebook or at drdennisgross.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222575305/en/
Contact information
For Shiseido Americas
Jadzia Zielinski Tirsch
Jonathan Leacock
jtirsch@sac.shiseido.com
jleacock@sac.shiseido.com
+1 212-805-2357
+1 212-805-1299
OR
FGS Global
Emily Claffey/Danya Al-Qattan/Bridget Nagle
Shiseido@fgsglobal.com
+1 212-687-8080
For Dr. Dennis Gross Skincare
Alyssa Keller D'Amico
Director of Content & Communications
alyssa.keller@dgskincare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Equiduct Expands into the Swiss Market15.5.2025 09:00:00 EEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
Allianz Reports Record Operating Profit and Is Fully on Track to Achieve Full-Year Outlook15.5.2025 08:26:00 EEST | Press release
May 15, 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514121549/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) 1Q 2025 Total business volume advances 11.71 percent to 54.0 billion euros reflecting sustained momentum across all segments Operating profit increases 6.3 percent to 4.2 billion euros, reaching 26 percent of our full-year outlook midpoint Shareholders’ core net income is stable at a very good level of 2.6 billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures, shareholders’ core net income is up 5 percent Core earnings per share grow 2.9 percent and reach 6.61 euros. Adjusted for the above-mentioned one-off tax provision, core earnings per share are up 7 percent Annualized core RoE is robust at 16.6 percent, or 17.2 percent adjusted for the effect of the one-off tax provision Solvency II capitalization ratio
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 07:01:00 EEST | Press release
Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuable beer brand in the world. Michelob ULTRA moved up one spot to #5 amongst beer brands globally. Michelob ULTRA has also been named the winner
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 07:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination criteria for the two awards are as follows: B2B Return On Integration (ROI) Honors. These awards showcase organizations that have achi
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom